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Fluorouracil has been in clinical use as an anticancerdrug for 30 years. Although this drug has
a broad spectrum of anticancer activity, including significant activity against the common solid
tumors of the gastrointestinal system, only a minority of patients treated with fluorouracil
experience anobjective response totherapy. Furthermore, in randomized clinical trials completed
todate, it has not been possible todemonstrate that fluorouracil therapy significantly prolongs the
life span ofpatients with advanced cancer.
Recent laboratory studies have indicated that leucovorin can enhance the cytotoxicity of
fluorouracil in vitro, evidently by enhancing inhibition of the key enzyme, thymidylate synthe-
tase, by the fluorouracil metabolite, FdUMP (fluorodeoxyuridine monophosphate; a stable
inactive FdUMP-reduced folate-thymidylate synthetase complex is formed). Pilot, uncontrolled
studies of leucovorin-fluorouracil combinations have suggested that leucovorin may significantly
increase both theclinical efficacy and theclinical toxicity offluorouracil in cancer patients. These
findings have led to the initiation of several randomized, controlled studies of leucovorin plus
fluorouracil versus fluorouracil alone in the treatment of patients with advanced colorectal
cancer. Three of these studies have recently completed patient accrual, and the preliminary
results ofeach ofthe three studies indicate that leucovorin-fluorouracil combinations will have a
better therapeutic index than fluorouracil used alone in this disease. Further follow-up of these
studies will be needed to determine whether leucovorin-fluorouracil combination therapy will
prolong the life span ofpatients with colorectal cancer.
INTRODUCTION
The modern era of cancer chemotherapy began at Yale more than 40 years ago,
when Goodman, Gilman, and Doherty found that nitrogen mustard therapy produced
substantial palliation in patients with Hodgkin's lymphoma [1]. Since then, major
advances have been made in the chemotherapy of a number of forms of cancer.
Unfortunately, effective chemotherapy regimens are not yet available for some of the
most common forms of cancer, including most forms of lung cancer and the most
common cancers ofthe gastrointestinal system.
Fluorouracil was discovered by Heidelberger and colleagues at the University of
Wisconsin some 30 years ago [2]. Although fluorouracil does not have a high level of
anticancer activity, it does have a broad spectrum of activity against human solid
tumors. In particular, fluorouracil is generally regarded as the most activesingle agent
currently available forthechemotherapy ofadenocarcinomas ofthecolon, rectum, and
pancreas. Colorectal cancer and pancreatic cancer are the two most common gastroin-
testinal cancers in the United States and are the second and fifth leading causes of
cancer death. In 1987, about 60,000 patients will die of colorectal cancer and about
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24,000 patients will die of pancreatic cancer in the U.S. [3]. Fluorouracil also has
significant clinical activity against several other forms ofcancer and is included in the
standard treatment regimens for breast cancer and gastric cancer.
In the chemotherapy of colorectal cancer, fluorouracil, used alone, continues to be
the standard against which newer chemotherapeutic regimens must be compared.
Although objective response rates of 8 to 85 percent have been reported in colorectal
cancer patients treated with fluorouracil [4], it is generally accepted that standard
fluorouracil treatment regimens will produce a 15-20 percent objective response rate
in patients receiving fluorouracil as their first chemotherapy following diagnosis of
advanced colorectal cancer. Since such a small proportion of patients experience a
clear benefit, it is not surprising that randomized studies have never shown a
statistically significant survival benefit attributable to fluorouracil therapy for this
disease (although there may be a significant survival benefit for those patients who do
respond). The best survival results in a randomized trial offluorouracil in patients with
colorectal cancer were obtained byAnsfield andcolleagues [5]; in that study, there was
a trend to improved survival in patients who received a relatively aggressive (and more
toxic) fluorouracil treatment regimen, but this trend did not achieve statistical
significance at thep < .05 level.
A great deal of clinical research has been directed toward finding ways to increase
the level of anticancer activity of this drug. Other drugs have been administered in
attempts to (1) increase the formationofactive metabolites offluorouracil; (2) decrease
the rate of catabolism of fluorouracil; or (3) decrease the level of normal uracil
metabolites, which compete with fluorouracil metabolites and lessen their effective-
ness. Other drugs utilized in these past clinical studies have included methotrexate,
phosphono-N-acetyl-L-aspartic acid (PALA), pyrazofurin, thymidine, and others [6].
The possible benefits of these approaches have yet to be demonstrated in definitive,
controlled clinical trials.
MECHANISMS OF FLUOROURACIL ACTION:
EFFECTS OF LEUCOVORIN
Three biochemical actions of fluorouracil are presently regarded as potentially
important mechanisms of fluorouracil cytotoxicity. These include (1) conversion to
fluorouridine triphosphate, which is incorporated into RNA and interferes with RNA
function; (2) conversion to fluorodeoxyuridine monophosphate (FdUMP), which binds
to and inhibits the enzyme thymidylate synthetase, thereby starving the cell for
thymidylic acid, which is of critical importance for DNA repair and replication; and
(3) conversion to fluorodeoxyuridine triphosphate (FdUTP), which may be incorpo-
rated into DNA and then undergo rapid removal from DNA, leaving breaks in the
DNA (ifa large number ofbreaks are generated, the DNA may befragmented) [6-8].
There are additional, more subtle biochemical effects of fluorouracil which could also
be important; these have been reviewed in detail previously [6] and will not be further
discussed here.
The roles that each of these various biochemical effects play in the efficacy and
toxicities of fluorouracil are not yet clear. However, studies conducted by Houghton
and colleagues in human colorectal cancer xenografts maintained in immune-
compromised mice [9], andstudiesconducted more recentlyby Rustum and colleagues
on tumor biopsy specimens obtained from colorectal cancer patients treated with
fluorouracil [10], have suggested that effective inhibition of thymidylate synthetase
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phate.
may be a critical determinant of the clinical efficacy of fluorouracil in colorectal
cancer.
Leucovorin appears selectively to enhance the inhibition of thymidylate synthetase
in fluorouracil-treated cells. As noted above, the fluorouracil metabolite, FdUMP,
binds to and inhibits thymidylate synthetase. This binding is rather weak and readily
reversible. If, however, there are adequate intracellular levels of the reduced folate
cofactor 5, 10-methylene-tetrahydrofolate, this cofactor will bind to the FdUMP-TS
complex to produce a ternary complex which is extremely stable [11]; this action
results in prolonged, effective inhibition ofthymidylate synthetase. Figure 1 illustrates
the thymidylate synthetase reaction, its inhibition by FdUMP, and the mechanism by
which reduced folate can enhance FdUMP inhibition of TS. Ullman and colleagues
[12] and Evans and colleagues [13] have shown that exposure ofcancer cells in culture
to increasing levels of reduced folate (leucovorin) renders these cells much more
sensitive to the cytotoxicity offluorouracil and other fluoropyrimidines, by allowing for
more effective inhibition of thymidylate synthetase on exposure of these cells to
fluoropyrimidines. Pharmacologic levels of leucovorin (10 micromolar or more) are
required for optimal enhancement offluorouracil cytotoxicity in vitro [13].
Past attempts to improve the clinical therapeutic index of fluorouracil by adminis-
tration ofa second drug havegenerally utilized drugs which non-selectively enhance all
of the biochemical actions of fluorouracil. Assuming that the clinical efficacy of
fluorouracil is due primarily to its effects on thymidylate synthetase, and that the other
biochemical effects of fluorouracil may contribute to toxicity but not to efficacy,
selective enhancement of thymidylate synthetase inhibition in fluorouracil-treated
patients (as may be achieved with leucovorin) could be a more successful approach to
improving the therapeutic index ofthis drug.
LEUCOVORIN PLUS FLUOROURACIL: PILOT CLINICAL STUDIES
As noted above, in vitro studies have suggested that extracellular levels ofleucovorin
should be 10 micromolar or greater at the time ofcellular exposure to fluorouracil, for
maximal enhancement of thymidylate synthetase inhibition and cytotoxicity. There-
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TABLE 1
Clinical Pharmacology of Leucovorin: Selected Parameters
Half-Times
(minutes)
Concentration
Treatment Regimen Folate Measured (,gM) a /3 Mean Reference
200 mg/M2 intravenous bolus Leucovorin 43a 20 122 - [14]
5-Methyl-tetrahydrofolate 2a 362 -
(metabolite)
500 mg/m2/day intravenous Leucovorin 4.5b - - 53C [15]
infusion
5-Methyl-tetrahydrofolate 4.7 - - 167C
(metabolite)
500 mg/m2/two-hour intrave- Leucovorin 11 a - - 414d [10,16]
nous infusion
5-Methyl-tetrahydrofolate 12a - - 336
"Peak concentrations (Regimens were designed to maintain 10 micromolar or higher leucovorin levels for
one hour after fluorouracil injection.)
bSteady-state concentrations
cPost-infusion half-times
dAssay measured both d and I isomers. Only d isomer remained by one to two hours post-infusion.
fore, clinical studies of leucovorin plus fluorouracil in cancer patients have generally
utilized large doses of leucovorin, to produce plasma levels of reduced folate of 10
micromolar or higher. The more commonly used leucovorin/fluorouracil treatment
regimens, and aspectsoffolatepharmacology andpharmacokinetics inpatients treated
with these regimens, are presented in Table 1.
The first large pilot (uncontrolled) study of a leucovorin/fluorouracil treatment
regimen in cancer patients was completed by Machover and colleagues in Villejuif,
France [14]. Patients weretreated daily for five days with a bolus intravenous injection
ofleucovorin, 200 mg/M2, followed immediately by a fluorouracil intravenous infusion
administered over fifteen minutes. Patients generally received 370 mg of fluorouracil
per m2 perday in the first course oftherapy, with adjustment ofthe fluorouracil dosage
in subsequent courses of therapy depending on tolerance. Courses were repeated at
28-day intervals. The primary toxicities observed using this treatment were oral
mucositis and diarrhea, each ofwhich occurred in 25-30 percent oftreatment courses
and each of which was severe (grade 3) in 3-4 percent of treatment courses which
included fluorouracil at a dose of 370 mg/m2/day. Myelosuppression was less
common, rarely severe (1-2 percent grade 3 or above neutropenia or thrombopenia at
this dose), and rapidly reversible [14,17]. Rather impressive response rates were
observed in this early, uncontrolled study (refer to Tables 2 and 3). A number of
additional uncontrolled studies, utilizing this and other leucovorin/fluorouracil treat-
mentregimens in several formsofcancer, have been reported in the past few years. The
results of some ofthe larger published uncontrolled studies in patients with colorectal
cancer, and in patients with other malignancies, are summarized in Tables 2 and 3,
respectively. The tremendous variation in objective response rates observed in colorec-
tal cancer patients treated with leucovorin/fluorouracil regimens is reminiscent of the
8 to 85 percent range in response rates reported in different studies of the efficacy of
fluorouracil used as a single agent in colorectal cancer patients. Conclusions regarding
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the effect of leucovorin on the therapeutic index of fluorouracil in colorectal cancer
cannot be drawn from these uncontrolled studies; however, the results of uncontrolled
studies have been considered positive enough by clinical investigators to warrant
proceeding to randomized clinical trials comparing several leucovorin/fluorouracil
treatment regimens to standard fluorouracil regimens in colorectal cancer patients (see
the section following). The uncontrolled studies have also served to characterize the
effects ofleucovorin on the toxicities offluorouracil. In brief, although patients treated
with leucovorin/fluorouracil combination regimens experience the same spectrum of
toxicities as patients treated with fluorouracil alone, stomatitis and diarrhea appear to
be more prominent in patients treated with leucovorin/fluorouracil, while myelosup-
pression is more prominent in patients receiving fluorouracil alone.
Uncontrolled studies of leucovorin/fluorouracil regimens have also been carried out
in patients with several other forms of cancer. The results of published studies in
patients with breast cancer and in patients with gastric cancer are presented inTable 3.
The reported objective response rates in these patients are impressive by historical
standards. Again, randomized controlled studies will be required to assess definitively
the contribution of leucovorin to the therapeutic index of fluorouracil in these
diseases.
LEUCOVORIN PLUS FLUOROURACIL: RANDOMIZED
CONTROLLED STUDIES
Six randomized, controlled studies comparing leucovorin plus fluorouracil versus
fluorouracil alone in the treatment of patients with advanced colorectal cancer have
been initiated to date in the United States and Canada, and a seventh study is ongoing
in Italy. The design and current status ofthese studies are summarized in Table 4. As
noted, three studies have completed patient accrual.
Doroshow and colleagues at the City of Hope Medical Center have completed
patient accrual to their trial, comparing moderate doses of fluorouracil used alone
versus the same doses of fluorouracil administered together with infusion of a large
dose of leucovorin [29]. As indicated in Table 5, patients receiving leucovorin plus
fluorouracil experienced a substantially higher objective response rate (45 percent
versus 15 percent), and a significantly longer median time to progression. There is a
trend toward improved survival in the patients who received leucovorin plus fluoroura-
cil, but this trend has not yet reached statistical significance. The strength ofthis trend
may have been reduced by the study design, which allowed patients on the control arm
to cross over to the leucovorin plus fluorouracil arm; most of the patients who were
entered on the control arm did in fact eventually cross over to the experimental arm.
Hematologic toxicity was mild on both arms of the study; stomatitis was significantly
more severe in patients receiving leucovorin plus fluorouracil.
Petrelli and colleagues at Roswell Park Memorial Institute have completed patient
accrual for their trial, comparing an aggressive loading dose fluorouracil alone control
arm versus a weekly fluorouracil-high dose leucovorin experimental arm [30]. As
noted in Table 5, patients treated with leucovorin plus fluorouracil experienced a
significantly higher response rate (48 percent versus 11 percent) than patients treated
with fluorouracil alone. To date, there is a slight trend to improved survival in the
patients who received leucovorin plus fluorouracil, but it is unlikely that this trend will
ever reach statistical signficance in this small study. Diarrhea was more common in
patients receiving leucovorin plus fluorouracil, while leukopenia was more common in
patients receiving fluorouracil alone.
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TABLE 4
Leucovorin Plus Fluorouracil: Controlled Studies in Colorectal Cancer
Investigators Study Treatment Arms Study Status
Doroshow et al.
[29]
Petrelli et al.
[30]
Erlichman et al.
[31]
Northern California
Oncology Groupb
[32]
Canobbio et al.
[33]
GI Tumor Study
Groupb
North Central Cancer
Treatment Group-
Mayob
Control:
Fluorouracil 370 mg/m2/day x 5 days
Experimental:
Leucovorin 500 mg/m2/day x 6 (infusion)
Fluorouracil 370 mg/m2/day x 5 days
Control:
Fluorouracil 450 mg/m2/day x 5 days, then 200
mg/m2 alternate days to toxicity
Experimental:
Leucovorin 500 mg/m2/week (2-hour infusion)
Fluorouracil 600 mg/m2/week
Control:
Fluorouracil 370 mg/m2/day x 5 days
Experimental:
Leucovorin 200 mg/m2/day x 5 days
Fluorouracil 370 mg/m2/day x 5 days
Control:
Fluorouracil 12 mg/kg/day x 5 days, then 15 mg/
kg/week
Experimental:
Leucovorin 200 mg/m2/day x 5 days
Fluorouracil 400 mg/m2/day x 5 days
Control:
Fluorouracil 600 mg/m2/week
Experimental:
Leucovorin 500 mg/m2/week (2-hour infusion)
Fluorouracil 600 mg/m2/week
Control:
Fluorouracil 500 mg/m2/day x 5 days
Experimental No. 1:
Leucovorin 500 mg/m2/week (2-hour infusion)
Fluorouracil 600 mg/m2/week
Experimental No. 2:
Leucovorin 25 mg/m2/week (10-minute infusion)
Fluorouracil 600 mg/m2/week
Control:
Fluorouracil 500 mg/m2/day x 5 days
Experimental No. 1:
Leucovorin 200 mg/m2/day x 5 days
Fluorouracil 370 mg/m2/day x 5 days
Experimental No. 2:
Leucovorin 20mg/m2/day x 5 days
Fluorouracil 425 mg/m2/day x 5 days
Accrual complete
(79 patients total)
Accrual complete
(44 patients total)
Accrual complete
(130 patients total)
Ongoing; planned ac-
cruals, 70 patients
(control) and 140
patients (experi-
mental)
Ongoing
(67 patients ac-
crued)
Ongoing
Ongoing; planned ac-
crual of70 patients
per arm, with ex-
tension to 140 pa-
tients per arm pos-
sible
'Most studies allow dose adjustments in second and subsequent treatment courses, depending on toxicity.
"These studies include additional arms which test other therapeutic approaches.
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TABLE 5
Leucovorin Plus Fluorouracil Versus Fluorouracil Alone: Preliminary Results of Controlled Trials
in Colorectal Cancer
Objective Response
Investigators Ratesa Toxicity Comparison
Doroshow et al. [29] Fluorouracil alone: 15% More stomatitis observed on leucovorin/fluo-
Leucovorin/fluorouracil: 45% rouracil
Petrelli et al. [30] Fluorouracil alone: 11% Diarrhea predominant on leucovorin/fluorou-
Leucovorin/fluorouracil: 48% racil; myelosuppression predominant on flu-
orouracil alone
Erlichman et al. [31] See text More stomatitis, diarrhea, and myelosuppres-
sion on first course with leucovorin/fluorou-
racil; toxicity more equal in subsequent
courses, following dose adjustments
Valone et al. [32] No data published More myelosuppression and diarrhea on the
aggressive fluorouracil alone control arm
Canobbio et al. [33] Fluorouracil alone: 4% Slightly more toxicity (stomatitis, diarrhea,
Leucovorin/fluorouracil: 21% myelosuppression) on leucovorin/fluoroura-
cil
'Objective complete plus partial response rates, as published by the investigators
Although Erlichman and colleagues (Princess Margaret Hospital, Toronto, and
Tom Baker Cancer Clinic, Calgary) have completed patient accrual to their study,
only partial results have been published to date [31]. This study compared moderate
doses of fluorouracil used alone, versus the same doses of fluorouracil administered
with high doses of leucovorin, in the first course oftherapy. Fluorouracil dosages were
adjusted in the second and subsequent coursesoftreatment, to achieveequal toxicity in
the two treatment arms. In the interim report on the first 52 evaluable patients,
objective responses were reported in ten patients on the leucovorin plus fluorouracil
arm, while no patients had responded to fluorouracil alone. Crossover of patients was
not allowed in this relatively large study, so the relative effects of the two treatment
arms on patient survival should be clearly discernible. Additional results from this
study should come out in the near future.
Accrual is ongoing in the Northern California Oncology Group study, which
compares an aggressive loading dose-maintenance dose fluorouracil alone control arm
with a commonly used leucovorin plus fluorouracil experimental arm [32]. To date,
only interim toxicity results are available from this study; these results indicate that
toxicities (particularly myelosuppression and diarrhea) are substantially more com-
mon and more severe in patients who are being treated on the fluorouracil alone control
arm.
Preliminary results of the study being conducted in Italy by Canobbio and
colleagues have recently been published [33]. This study compares weekly treatment
with a modest dose of fluorouracil alone versus a weekly fluorouracil-high-dose
leucovorin experimental arm. To date, objective responses have been observed in 1 of
23 evaluable patients on fluorouracil alone, and in 6 of 29 patients on leucovorin plus
fluorouracil (4 percent vs. 21 percent, not statistically significant). Patients receiving
leucovorin plus fluorouracil have experienced slightly more stomatitis, diarrhea, and
leukopenia.
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No results have been published to date from the ongoing North Central Cancer
Treatment Group-Mayo Clinic study or from the ongoing GI Tumor Study Group
study. In an effort to ensure definitive results, the North Central Cancer Treatment
Group-Mayo Clinic consortium has recently decided to double the accrual in selected
arms ofthis study, which will probably extend the patient accrual period for that study
to 1990 or beyond.
CONCLUSIONS
Although it will be several years before the last of the randomized studies is
concluded, all of the results which have come out ofthese studies to date indicate that
leucovorin will be shown to significantly enhance the therapeutic index of fluorouracil
in colorectal cancer. The improvement in therapeutic index could be substantial
enough to permit demonstration ofa statisticallysignificant survival benefit in patients
treated on the leucovorin/fluorouracil arm ofone or more ofthese studies. An efficacy
difference of this magnitude would most likely be evident in one of the studies
comparing a leucovorin/fluorouracil regimen to a moderate-dose fluorouracil alone
control arm (e.g., the Doroshow, Erlichman, and Canobbio studies), as it is clear that
moderate doses offluorouracil tend to be less active as well as less toxic than maximal
tolerated doses of this drug. Studies comparing leucovorin/fluorouracil regimens to
aggressive fluorouracil alone control arms will be less likely to show a clear efficacy
difference, but should still show a therapeutic index advantage for leucovorin/
fluorouracil (e.g., equal efficacy with less toxicity), if leucovorin does indeed enhance
the therapeutic index offluorouracil.
Assuming that leucovorin is shown to enhance the therapeutic index of fluorouracil
in colorectal cancer, potentially fruitful avenues for future research will include
addressing questions such as the following: What dose of leucovorin is optimal? Can
other reduced folates (or folic acid itself) provide the same clinical results? Will
leucovorin similarly enhance the therapeutic index of fluorouracil in other fluoroura-
cil-responsive tumors? Will leucovorin expand the spectrum of anticancer activity of
fluorouracil? How can leucovorin be used to best advantage in methotrexate/
fluorouracil combinations? What role does folate polyglutamylation play in the
leucovorin/fluorouracil interaction? Can leucovorin/fluorouracil be effective as adju-
vant therapy, to prevent recurrence ofcolorectal cancer after surgery?
Finally, although it appears that leucovorin/fluorouracil regimens could represent a
significant step forward in the treatment of colorectal cancer, it is clear that this is a
modest step. Although the addition of leucovorin could significantly improve the
therapeutic index of fluorouracil in advanced colorectal cancer and could lead to the
first demonstration of a statistically significant survival benefit in patients receiving
chemotherapy for thisdisease, it isclearthat fewer than halfofthepatients treated will
have an objective response; complete responses will still be rare, and response and
survival durations will still be relatively brief. But the history of progress in modern
cancerchemotherapy has been a history ofmodest steps likethis; major advances have,
in reality, been the result of a series of smaller steps. The symbolic importance of this
advance would be the demonstration that we can make progress even in the treatment
of this historically refractory form of cancer and that, given patience and hard work,
there is every reason to believe that we will ultimately devise effective medical
therapies for this cancer, and for other cancers that arecurrently refractory to our best
treatments.
32LEUCOVORIN AND FLUOROURACIL IN TREATMENT OF CANCER 33
REFERENCES
1. Goodman LS, Wintrobe MM, Dameshek W, et al: Nitrogen mustard therapy. JAMA 132:126-132,
1946
2. Heidelberger C, Chaudhari NK, Danneberg P, et al: Fluorinated pyrimidines. A new class of
tumor-inhibitory compounds. Nature 179:663-666, 1957
3. Silverberg E, Lubera J: Cancer statistics, 1987. Ca-A Cancer Journal for Clinicians 37:2-19, 1987
4. Moertel CG: Large bowel. In Cancer Medicine. Edited by JF Holland, E Frei. Philadelphia, Lea and
Febiger, 1973, pp 1497-1626
5. Ansfield F, Klotz J, Nealon T, et al: A Phase 3 study comparing the clinical utility offour regimens of
5-fluorouracil. Cancer 39:34-40, 1977
6. Chabner BA: Pyrimidine antagonists. In Pharmacologic Principles ofCancer Treatment. Edited by BA
Chabner. Philadelphia, WB Saunders, 1982, pp 183-212
7. Scheutz JD, Wallace HJ, Diasio RB: 5-Fluorouracil incorporation into DNA of CF-I mouse bone
marrow cells as a possible mechanism oftoxicity. Cancer Res 44:1358-1363, 1984
8. Cadman E, Yabuki H: Enhanced base substitution and strand breakage following 5-fluoro-2'-
deoxyuridine incorporation into DNA. Proc Am Assoc Ca Res 25:17 (abstract 68), 1984
9. Houghton JA, Maroda SJ, Phillips JO, Houghton PJ: Biochemical determinants of responsiveness to
5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer
Res41:144-149, 1981
10. Rustum YM, Campbell J, Zakrewski S, et al: Pharmacokinetic and cellular determinants of 5-
fluorouracil in combination with high dose citrovorum factor in patients with advanced colorectal
carcinoma. Proc Am Assoc Ca Res 25:167 (abstract 661), 1984
11. Lockshin A, Danenberg PV: Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate
binding to human thymidylate synthetase. Biochem Pharmacol 30:247-257, 1981
12. Ullman B, Lee M, Martin DW, Santi DV: Cytotoxicity of 5-fluoro-2'-deoxyuridine: requirement for
reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci USA 75:980-983, 1978
13. Evans RM, Laskin JD, Hakala MT: Effect ofexcess folates and deoxyinosine on the activity and site of
action of 5-fluorouracil. Cancer Res 41:3283-3295, 1981
14. Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric
adenocarcinomas with 5-fluorouracil and high dose folinic acid. J Clin Oncol 4:685-696, 1986
15. Newman E, Doroshow J, Bertrand M, et al: Pharmacokinetics ofhigh dose folinic acid administered by
continuous infusion. Proc Am Assoc Cancer Res 26:158 (abstract 627), 1985
16. Madajewicz S, Petrelli N, Rustum YM, et al: Phase 1-2 trial of high dose calcium leucovorin and
5-fluorouracil in advanced colorectal cancer. Cancer Res 44:4667-4669, 1984
17. Machover D, Schwarzenberg L, Goldschmidt E, et al: Treatment of advanced colorectal and gastric
adenocarcinomas with 5-FU combined with high dose folinic acid: a pilot study. Cancer Treat Rep
66:1803-1807, 1982
18. Bertrand M, Doroshow J, Multhauf P, et al: High dose continuous infusion folinic acid and bolus
5-fluorouracil in patients with advanced colorectal cancer: a phase 2 study. J Clin Oncol 4:1058-1061,
1986
19. Zakem M, Hines JD, Adelstein DJ, Rustum YM: High dose leucovorin and 5-fluorouracil in refractory
and relapsed colorectal carcinoma. Proc Am Soc Clin Oncol 5:81 (abstract 315), 1986
20. Valone FH, Kohler M, Fisher K, et al: A NCOG randomized trial of5-FU vs high dose leucovorin plus
5-FU vs sequential methotrexate, 5-FU, leucovorin for patients with advanced colorectal carcinoma.
Proc Am Soc Clin Oncol 5:89 (abstract 348), 1986
21. Greene H, Desai A, Levick S, Tester W: Combined 5-fluorouracil infusion and high dose folinic acid in
the treatment ofmetastatic gastrointestinal cancer. Proc Am Soc Clin Oncol 5:89 (abstract 347), 1986
22. Cunningham J, Bukowski RM, Budd GT, et al: 5-fluorouracil and folinic acid: a Phase 1-2 trial in
gastrointestinal malignancy. Inv New Drugs 2: 391-395, 1984
23. Budd GT, Fleming TR, Bukowski RM, et al: 5-fluorouracil and folinic acid in the treatment of
metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group study. J Clin
Oncol 5:272-277, 1987
24. Schmoll HJ, Le Blanc S: Sequential high dose folinic acid and 5-fluorouracil in advanced colorectal
cancer with measurable, progressive disease. Proc Am Soc Clin Oncol 4:94 (abstract C-367), 1985
25. Sanzo KA, Brunetti M, Earle MF, et al: Confirmation ofactivity ofleucovorin/5-fu in metastatic colon
carcinoma. Proc Am Soc Clin Oncol 6:76 (abstract 295), 198734 ROBERT J. DeLAP
26. Arbuck SG, Douglass HO, Nava H, et al: A phase 2 study of5-fluorouracil and high dose folinic acid in
patients with gastric carcinoma. Proc Am Soc Clin Oncol 5:91 (abstract 354), 1986
27. Marini G, Marpicati P, Zaniboni A, et al: Treatment ofadvanced breast cancer with 5-fluorouracil and
high dose folinic acid: preliminary results. Chemioterapia 4:135-138, 1985
28. Doroshow, J, Bertrand M, Multhauf P, et al: High dose continuous infusion folinic acid and IV bolus
5-FU: an effective salvage regimen for refractory metastatic breast cancer. Proc Am Soc Clin Oncol
5:65 (abstract 252), 1986
29. Doroshow JH, Bertrand M, Multhauf P, et al: Prospective randomized trial comparing 5-FU versus
5-FU and high dose folinic acid for treatment ofadvanced colorectal cancer. Proc Am Soc Clin Oncol
6:96 (abstract 374), 1987
30. Petrelli N, Herrera L, Stulc J, et al: A phase 3 study of 5-fluorouracil versus 5-FU plus methotrexate
versus 5-FU plus high dose leucovorin in metastatic colorectal adenocarcinoma. Proc Am Soc Clin
Oncol 6:74 (abstract 286), 1987
31. Erlichman C, Fine S, Wong A, Elhakim T: A comparison of5-fluorouracil and folinic acid versus 5-FU
in metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 5:82 (abstract 319), 1986
32. Valone F, Medrano V, Yu KP, et al: Randomized trial of 5-FU, vs leucovorin plus 5-FU, vs sequential
methotrexate, 5-FU, leucovorin in patients with advanced colo-rectal carcinoma. A Northern California
Oncology Group Trial. Proc Am Soc Clin Oncol 6:78 (abstract 305), 1987
33. Canobbio L, Nobile MT, Galligioni E, et al: Randomized trial of5-fluorouracil alone or combined with
high dose folinic acid in advanced colorectal cancer patients. Proc Am Soc Clin Oncol 6:97 (abstract
381), 1987